Twist Bioscience CFO sells 2,085 shares for taxes

Twist Bioscience Corp Chief Financial Officer Adam Laponis reported an open-market sale of 2,085 shares of common stock of Twist Bioscience.

Rhea-AI Filing Summary

Twist Bioscience Corp Chief Financial Officer Adam Laponis reported an open-market sale of 2,085 shares of common stock of Twist Bioscience. The shares were sold at a weighted average price of $46.7098 per share to cover tax withholding obligations tied to vesting Restricted Stock Units, under a mandated “sell to cover” arrangement rather than at his discretion.

After this tax-related transaction, Laponis beneficially owns 128,291 shares of common stock, which include shares acquired under the company’s Employee Stock Purchase Plan in transactions exempt under Rule 16b-3(d) and Rule 16b-3(c).

Insider Trade Summary

Net Seller: 2,085 shares

Net Sell 1 txn

Insider Laponis Adam

Role Chief Financial Officer

Sold 2,085 shs ($97K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,085	$46.7098	$97K

Holdings After Transaction: Common Stock — 128,291 shares (Direct)

Footnotes (2)

1. F1. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
2. F2. Includes shares that were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).

FAQ

What insider transaction did Twist Bioscience (TWST) report for Adam Laponis?

Twist Bioscience reported that CFO Adam Laponis sold 2,085 common shares. The sale was an open-market transaction linked to tax withholding obligations from Restricted Stock Unit vesting, rather than a discretionary decision to reduce his investment.

Why did the Twist Bioscience (TWST) CFO sell 2,085 shares?

The 2,085 shares were sold to cover tax withholding obligations arising from vesting Restricted Stock Units. The company’s equity plans mandate a “sell to cover” transaction, meaning these sales are automatic and not voluntary portfolio adjustments by the CFO.

At what price were the Twist Bioscience (TWST) shares sold by the CFO?

The reported shares were sold at a weighted average price of $46.7098 per share. This reflects the average price across the open-market sale transactions executed to satisfy tax withholding requirements associated with the vesting of the CFO’s Restricted Stock Units.

How many Twist Bioscience (TWST) shares does the CFO hold after this transaction?

Following the sale, CFO Adam Laponis beneficially owns 128,291 shares of common stock. This total includes shares acquired through the company’s Employee Stock Purchase Plan, which were obtained in transactions exempt under Rule 16b-3(d) and Rule 16b-3(c).

Was the Twist Bioscience (TWST) CFO’s share sale a discretionary trade?

No. The filing states the sale was to cover tax withholding obligations and was mandated by Twist Bioscience’s equity incentive plans. It describes the transaction as a required “sell to cover” event, not a discretionary decision to sell shares on the open market.

What role does the Employee Stock Purchase Plan play in the CFO’s Twist Bioscience (TWST) holdings?

The filing notes that the CFO’s 128,291-share beneficial ownership includes shares acquired through the Employee Stock Purchase Plan. These acquisitions were executed in transactions exempt from certain insider rules under Rule 16b-3(d) and Rule 16b-3(c).

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/25/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Laponis Adam

(Last) (First) (Middle)

C/O TWIST BIOSCIENCE CORPORATION

681 GATEWAY BLVD

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/23/2026		S		2,085(1)	D	$46.7098	128,291(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

2. Includes shares that were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).

Remarks:

	/s/ Kendra Fox, as Attorney-in-Fact for Adam Laponis	02/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.